Hepatitis Monthly

Published by: Kowsar

Sero-Prevalence of Bloodborne Tumor Viruses (HCV, HBV, HTLV-I and KSHV Infections) and Related Risk Factors among Prisoners in Razavi Khorasan Province, Iran, in 2008

Mohammad Khajedaluee 1 , Ali Babaei 2 , Rosita Vakili 3 , Narges Valizade 1 , Fateme Homaei Shandiz 4 , Seyed Moayed Alavian 5 , 6 , Mohsen Seyed Nozadi 1 , Seyed Mohammad Jazayeri 7 and Tahereh Hassannia 8 , *
Authors Information
1 Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 University of Applied Science and Technology, Mashhad Branch Region 6, (Prison Organization), Mashhad, IR Iran
3 Center of Pathological and Medical Diagnostic Services, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, IR Iran
4 Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
6 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
7 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
8 Internal Medicine Department, Arash Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: December 01, 2016, 16 (12); e31541
  • Published Online: December 3, 2016
  • Article Type: Research Article
  • Received: July 16, 2015
  • Revised: November 28, 2015
  • Accepted: November 26, 2016
  • DOI: 10.5812/hepatmon.31541

To Cite: Khajedaluee M, Babaei A, Vakili R, Valizade N, Homaei Shandiz F, et al. Sero-Prevalence of Bloodborne Tumor Viruses (HCV, HBV, HTLV-I and KSHV Infections) and Related Risk Factors among Prisoners in Razavi Khorasan Province, Iran, in 2008, Hepat Mon. 2016 ; 16(12):e31541. doi: 10.5812/hepatmon.31541.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study. BMC Infect Dis. 2008; 8: 33[DOI][PubMed]
  • 2. Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention. Cancer Biol Ther. 2010; 10(10): 961-78[PubMed]
  • 3. Arjmand B, Aghayan SH, Goodarzi P, Farzanehkhah M, Mortazavi SM, Niknam MH, et al. Seroprevalence of human T lymphtropic virus (HTLV) among tissue donors in Iranian tissue bank. Cell Tissue Bank. 2009; 10(3): 247-52[DOI][PubMed]
  • 4. Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am Fam Physician. 2010; 82(10): 1225-9[PubMed]
  • 5. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28: 112-25[DOI][PubMed]
  • 6. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010; 52(4): 1497-505[DOI][PubMed]
  • 7. Zhang T, Shao X, Chen Y, Zhang T, Minhas V, Wood C, et al. Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis. 2012; 18(1): 150-2[DOI][PubMed]
  • 8. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005; 24(39): 6058-68[DOI][PubMed]
  • 9. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011; 52(3): 172-6[DOI][PubMed]
  • 10. Pebuara 2006. 2010;
  • 11. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol. 2012; 250(1-2): 87-93[DOI][PubMed]
  • 12. Shoeibi A, Etemadi M, Moghaddam Ahmadi A, Amini M, Boostani R. "HTLV-I Infection" Twenty-Year Research in Neurology Department of Mashhad University of Medical Sciences. Iran J Basic Med Sci. 2013; 16(3): 202-7[PubMed]
  • 13. Kalavi K, Moradi A, Tabarraei A. Population-based Seroprevalence of HTLV-I Infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci. 2013; 16(3): 225-8[PubMed]
  • 14. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003; 23(1): 39-46[DOI][PubMed]
  • 15. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9[DOI][PubMed]
  • 16. Ahmad B, Ali S, Ali I, Azam S, Bashir S. Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J. 2012; 9: 18[DOI][PubMed]
  • 17. Ahmadi Ghezeldasht S, Hassannia T, Rafatpanah H, Hekmat R, Valizadeh N, Ghayour Mobarhan M, et al. Oncogenic Virus Infections in the General Population and End-stage Renal Disease Patients With Special Emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran. Jundishapur J Microbiol. 2015; 8(3)[DOI][PubMed]
  • 18. Ali A, Lal A. False positivity of serological tests for hepatitis C virus. J Ayub Med Coll Abbottabad. 2010; 22(2): 43-5[PubMed]
  • 19. Cobo F. Application of molecular diagnostic techniques for viral testing. Open Virol J. 2012; 6: 104-14[DOI][PubMed]
  • 20. Storch GA. Diagnostic virology. Clin Infect Dis. 2000; 31(3): 739-51[DOI][PubMed]
  • 21. Vazquez-Martinez JL, Coreno-Juarez MO, Montano-Estrada LF, Attlan M, Gomez-Dantes H. Seroprevalence of hepatitis B in pregnant women in Mexico. Salud Publica Mex. 2003; 45(3): 165-70[PubMed]
  • 22. World prison population list 2007. 2007;
  • 23. Report on the global AIDS epidemics. UNAIDS 10th Anniversary Special editio. 2006;
  • 24. Javadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health. 2006; 35(4): 33-6
  • 25. Burek V, Horvat J, Butorac K, Mikulic R. Viral hepatitis B, C and HIV infection in Croatian prisons. Epidemiol Infect. 2010; 138(11): 1610-20[DOI][PubMed]
  • 26. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. J Infect Dev Ctries. 2010; 4(3): 144-9[PubMed]
  • 27. Nelwan EJ, Van Crevel R, Alisjahbana B, Indrati AK, Dwiyana RF, Nuralam N, et al. Human immunodeficiency virus, hepatitis B and hepatitis C in an Indonesian prison: prevalence, risk factors and implications of HIV screening. Trop Med Int Health. 2010; 15(12): 1491-8[DOI][PubMed]
  • 28. Saiz de la Hoya P, Marco A, Garcia-Guerrero J, Rivera A, Prevalhep study G. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011; 30(7): 857-62[DOI][PubMed]
  • 29. Treso B, Barcsay E, Tarjan A, Horvath G, Dencs A, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. J Urban Health. 2012; 89(1): 108-16[DOI][PubMed]
  • 30. Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon. 2012; 12(1): 23-31[DOI][PubMed]
  • 31. Azarkar Z, Sharifzadeh G. Evaluation of the Prevalence of Hepatitis B, Hepatitis C, and HIV in Inmates with Drug-Related Convictions in Birjand, Iran in 2008. Hepat Mon. 2010; 10(1): 26-30[PubMed]
  • 32. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5)-86[DOI][PubMed]
  • 33. Yasunaga J, Jeang KT. Viral transformation and aneuploidy. Environ Mol Mutagen. 2009; 50(8): 733-40[DOI][PubMed]
  • 34. Coelho HC, de Oliveira SA, Miguel JC, Oliveira Mde L, Figueiredo JF, Perdona GC, et al. Predictive markers for hepatitis C virus infection among Brazilian inmates. Rev Soc Bras Med Trop. 2009; 42(4): 369-72[PubMed]
  • 35. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62(4): 305-13[DOI][PubMed]
  • 36. Jalilvand S, Shoja Z, Mokhtari-Azad T, Nategh R, Gharehbaghian A. Seroprevalence of Human herpesvirus 8 (HHV-8) and incidence of Kaposi's sarcoma in Iran. Infect Agent Cancer. 2011; 6: 5[DOI][PubMed]
  • 37. Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat Mon. 2011; 11(5): 346-50[PubMed]
  • 38. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in IR IRAN. Gastroenterol Hepatol Bed Bench. 2009; 3(1)
  • 39. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003; 299(5613): 1713-6[DOI][PubMed]
  • 40. Ansaldi F, Comar M, D'Agaro P, Grainfenberghi S, Caimi L, Gargiulo F, et al. Seroprevalence of HTLV-I and HTLV-II infection among immigrants in northern Italy. Eur J Epidemiol. 2003; 18(6): 583-8[PubMed]
  • 41. Catalan-Soares BC, Almeida RT, Carneiro-Proietti AB. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among prison inmates at Manhuacu, Minas Gerais State, Brazil. Rev Soc Bras Med Trop. 2000; 33(1): 27-30[PubMed]
  • 42. Fialho M, Messias M, Page-Shafer K, Farre L, Schmalb M, Pedral-Sampaio D, et al. Prevalence and risk of blood-borne and sexually transmitted viral infections in incarcerated youth in Salvador, Brazil: opportunity and obligation for intervention. AIDS Behav. 2008; 12(4 Suppl)-24[DOI][PubMed]
  • 43. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. [HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counselling on the compliance of proposed tests]. Epidemiol Prev. 2004; 28(3): 163-8[PubMed]
  • 44. Adoga MP, Banwat EB, Forbi JC, Nimzing L, Pam CR, Gyar SD, et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries. 2009; 3(7): 539-47[PubMed]
  • 45. Anwar MS, Nafees M, Nabi U. Sero-prevalence of HCV and associated infections with HIV and HBV among prisoners in Lahore. Biomedica. 2011; 27(2): 119-1122
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments